Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes

Amy E. DeZern, Gary Binder, Syed Rizvi, Frank A. Corvino, Steven R. Arikian, Andy Surinach, Jianyi Lee, B. Douglas Smith

Research output: Contribution to journalArticlepeer-review

Abstract

Transfusion dependence (TD) among myelodysplastic syndromes (MDS) patients negatively impacts survival and health-related quality of life. We evaluated cost patterns of MDS care during TD and transfusion independence (TI). MDS patients were identified from a US claims database (2008–2013). TD was defined as ≥2 consecutive 8-week periods with ≥1 claim during each, and no interim 56-day period without transfusion; TI as 8 subsequent transfusion-free weeks; and transfusion frequency as the mean interval between transfusions during the TD period. 13,741 patients were included; 19% were TD and 70% had a mean interval between transfusions of ≤28 days. During a 2-year period, TD patients incurred a mean total cost of $17,815/patient-month; 53% higher for those with ≤28 days ($19,498) vs. >28 days ($12,717) between transfusions. Among patients who achieved TI, mean total cost was $7874/patient-month. For TD-MDS patients, cost increases are proportional to transfusion frequency and achieving TI yields economic benefits.

Original languageEnglish (US)
Pages (from-to)2649-2656
Number of pages8
JournalLeukemia and Lymphoma
Volume58
Issue number11
DOIs
StatePublished - Nov 2 2017

Keywords

  • Myelodysplastic syndromes
  • cost
  • health-related quality of life
  • transfusion dependence
  • transfusion independence

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this